Short Interest in Defence Therapeutics Inc. (OTCMKTS:DTCFF) Declines By 96.6%

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 100 shares, a decline of 96.6% from the February 13th total of 2,900 shares. Based on an average trading volume of 10,600 shares, the days-to-cover ratio is currently 0.0 days.

Defence Therapeutics Price Performance

Shares of DTCFF traded up $0.07 during trading hours on Wednesday, reaching $1.00. The company’s stock had a trading volume of 900 shares, compared to its average volume of 20,078. The company has a 50 day moving average of $0.70 and a two-hundred day moving average of $0.51. Defence Therapeutics has a 1-year low of $0.27 and a 1-year high of $1.32.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.